Renaissance Technologies LLC Has $1.54 Million Position in Korro Bio, Inc. $KRRO

Renaissance Technologies LLC raised its position in Korro Bio, Inc. (NASDAQ:KRRO) by 81.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 136,227 shares of the company’s stock after purchasing an additional 61,327 shares during the quarter. Renaissance Technologies LLC’s holdings in Korro Bio were worth $1,542,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Nantahala Capital Management LLC acquired a new position in shares of Korro Bio in the fourth quarter valued at approximately $4,806,000. TCG Crossover Management LLC acquired a new stake in Korro Bio during the 3rd quarter worth approximately $19,937,000. Vanguard Group Inc. grew its holdings in Korro Bio by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 395,659 shares of the company’s stock worth $18,948,000 after acquiring an additional 8,921 shares during the last quarter. Polar Capital Holdings Plc grew its holdings in Korro Bio by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 264,694 shares of the company’s stock worth $12,676,000 after acquiring an additional 14,694 shares during the last quarter. Finally, Millennium Management LLC increased its position in Korro Bio by 1.8% in the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after acquiring an additional 4,650 shares during the period. 13.18% of the stock is currently owned by institutional investors.

Korro Bio News Summary

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts across 2026 and 2027. The firm now expects a smaller loss of $4.88 per share for fiscal 2026, compared with its prior estimate of $5.81, and a $5.04 loss for fiscal 2027 versus its previous forecast of $6.23. Quarterly estimates were also revised to show narrower losses. The analyst maintained a Buy rating and a $15 price target, indicating potential upside from recent trading levels. Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Halozyme (HALO) and Resmed (RMD)
• Neutral Sentiment: Short-interest data provides no meaningful signal. A report listed short interest at zero shares as of August 11, unchanged from the prior period, with a zero-day days-to-cover ratio. However, the reported percentage change was shown as “NaN,” suggesting a data or reporting issue rather than a substantive change in investor positioning.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Lifesci Capital raised shares of Korro Bio to a “strong-buy” rating in a research note on Friday, May 29th. Wall Street Zen upgraded Korro Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright cut their target price on Korro Bio from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a research report on Monday, July 6th. Finally, JonesTrading raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Korro Bio Price Performance

NASDAQ KRRO opened at $13.35 on Thursday. The stock has a market capitalization of $196.65 million, a P/E ratio of -1.33 and a beta of 3.04. The business has a 50 day simple moving average of $12.30 and a 200 day simple moving average of $12.16. Korro Bio, Inc. has a one year low of $5.20 and a one year high of $55.89.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.27. The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $0.21 million. Korro Bio had a negative return on equity of 114.26% and a negative net margin of 1,834.48%. Equities analysts expect that Korro Bio, Inc. will post -4.97 earnings per share for the current year.

Insider Activity at Korro Bio

In other Korro Bio news, Director Jean Francois Formela sold 119,005 shares of Korro Bio stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $14.25, for a total value of $1,695,821.25. Following the completion of the sale, the director directly owned 176,649 shares of the company’s stock, valued at approximately $2,517,248.25. The trade was a 40.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ram Aiyar sold 15,152 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $12.98, for a total transaction of $196,672.96. Following the transaction, the chief executive officer owned 74,848 shares in the company, valued at $971,527.04. This represents a 16.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 306,026 shares of company stock worth $4,309,637 over the last quarter. 4.80% of the stock is currently owned by insiders.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.